1. Home
  2. GYRE vs TREE Comparison

GYRE vs TREE Comparison

Compare GYRE & TREE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$5.99

Market Cap

575.4M

Sector

Health Care

ML Signal

HOLD

Logo LendingTree Inc.

TREE

LendingTree Inc.

HOLD

Current Price

$37.05

Market Cap

541.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
GYRE
TREE
Founded
2002
1996
Country
United States
United States
Employees
618
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
575.4M
541.5M
IPO Year
2004
2008

Fundamental Metrics

Financial Performance
Metric
GYRE
TREE
Price
$5.99
$37.05
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$17.00
$71.25
AVG Volume (30 Days)
90.0K
174.3K
Earning Date
05-08-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
443.31
EPS
N/A
1.22
Revenue
$275,000.00
$1,117,324,000.00
Revenue This Year
$19.88
$19.03
Revenue Next Year
N/A
$7.07
P/E Ratio
N/A
$30.20
Revenue Growth
N/A
24.12
52 Week Low
$5.44
$32.65
52 Week High
$9.42
$77.35

Technical Indicators

Market Signals
Indicator
GYRE
TREE
Relative Strength Index (RSI) 42.36 45.53
Support Level $5.44 $34.50
Resistance Level $8.13 $40.00
Average True Range (ATR) 0.31 1.48
MACD 0.06 0.22
Stochastic Oscillator 45.08 38.91

Price Performance

Historical Comparison
GYRE
TREE

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

About TREE LendingTree Inc.

LendingTree Inc. is a U.S.-based company that mainly operates an online loan marketplace. The company offers online tools and resources to help consumers find loans or other credit-based products, including mortgage loans, reverse mortgages, home equity loans, personal loans, auto loans, credit cards, student loans, small business loans, and various related products. It provides consumers with direct access to a wide array of lenders. The company has three reportable segments: Home, Consumer, and Insurance. It generates match fees by connecting consumers with lenders and closing fees from lenders when a transaction is finalized. The company conducts business solely in the United States.

Share on Social Networks: